Midatech is an international specialty pharmaceutical company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.

Midatech is commercialising oncology treatment and supportive care products via its US Commercial Organisation, Midatech Pharma US. In Europe, Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of Cancer, Endocrine Disorders such as Diabetes, and Immunotherapy for autoimmune diseases.

Midatech’s strategy is to expand it US commercial arm as well as develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Midatech 2016 Annual General Meeting is to be held on Wednesday 11 May 2016 – Click here to view AGM notice
Download Midatech 2015 Final Results Presentation Click here
Latest News...
Apr 26, 2016
~ Release profile of Midatech’s Q-Octreotide compared favourably with the reference product and current... Read More
Apr 21, 2016
~ Programme is delivering on track for an IND in H2 2017 ~ Midatech Pharma (AIM: MTPH; Nasdaq: MTP),... Read More
Apr 13, 2016
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on... Read More



Privacy and cookie policy


  © Copyright 2014 Midatech